依达拉奉右莰醇在急性缺血性卒中脑细胞保护中的研究进展OA

Brain cytoprotection has long been a highly regarded yet challenging research direction in the field of acute ischemic stroke treatment.In the era of reperfusion therapy,with continuous advances in intravenous thrombolysis and endovascular therapy,the therapeutic goals of ischemic stroke have extended beyond large vessel recanalization to meaningful tissue-level benefit.Practical clinical demands such as alleviating ischemia-reperfusion injury,stabilizing the neurovascular unit,and expanding salvageable brain tissue have brought brain cytoprotection research back to the clinical forefront.Edaravone dexborneol,a compound preparation of edaravone and dexborneol,exerts multi-target effects including scavenging oxygen free radicals and inhibiting the inflammatory cascade,and has become one of the most evidence-based agents for brain cytoprotection in ischemic stroke in China.In recent years,relevant Chinese guidelines have gradually recommended it as an available brain cytoprotective agent,whereas international guidelines have not yet made routine recommendations for the clinical use of brain cytoprotective agents but have acknowledged renewed research opportunities in the context of reperfusion therapy for ischemic stroke.This review summarises the research background of brain cytoprotective agents,the positioning of brain cytoprotective strategies in international guidelines,and the pharmacological basis and current evidence for edaravone dexborneol.It summarises the design features,main findings,and clinical implications of key randomized controlled trials and real-world cohort studies in this field.Additionally,based on ongoing registered studies,it discusses future prospects of edaravone dexborneol in pre-hospital ultra-early intervention for ischemic stroke,combination treatment with reperfusion therapy,and application in precisely stratified or special populations,aiming to provide a reference for research and clinical practice in brain cytoprotection for ischemic stroke.